These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 35884895)
1. Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists. Andón FT; Leon S; Ummarino A; Redin E; Allavena P; Serrano D; Anfray C; Calvo A Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884895 [TBL] [Abstract][Full Text] [Related]
2. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365 [TBL] [Abstract][Full Text] [Related]
3. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088 [TBL] [Abstract][Full Text] [Related]
4. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies. Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS Front Immunol; 2020; 11():1112. PubMed ID: 32595636 [TBL] [Abstract][Full Text] [Related]
5. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy. Lee SN; Jin SM; Shin HS; Lim YT Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047 [TBL] [Abstract][Full Text] [Related]
6. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma. Xun Y; Yang H; Kaminska B; You H J Hematol Oncol; 2021 Oct; 14(1):176. PubMed ID: 34715891 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic Implications of Toll-like Receptors Activation in Tumor Microenvironment. Zheng R; Ma J Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365103 [TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy. Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358 [TBL] [Abstract][Full Text] [Related]
9. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy. Chakraborty S; Ye J; Wang H; Sun M; Zhang Y; Sang X; Zhuang Z Front Immunol; 2023; 14():1227833. PubMed ID: 37936697 [TBL] [Abstract][Full Text] [Related]
10. Trial watch: Toll-like receptor ligands in cancer therapy. Le Naour J; Kroemer G Oncoimmunology; 2023; 12(1):2180237. PubMed ID: 36875550 [TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma. Stone GW; Barzee S; Snarsky V; Santucci C; Tran B; Langer R; Zugates GT; Anderson DG; Kornbluth RS PLoS One; 2009 Oct; 4(10):e7334. PubMed ID: 19812695 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122 [TBL] [Abstract][Full Text] [Related]
18. Toll-Like Receptors and the Response to Radiotherapy in Solid Tumors: Challenges and Opportunities. Haroun R; Naasri S; Oweida AJ Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112730 [TBL] [Abstract][Full Text] [Related]
19. Toll-Like Receptor 9 Agonists in Cancer. Karapetyan L; Luke JJ; Davar D Onco Targets Ther; 2020; 13():10039-10060. PubMed ID: 33116588 [TBL] [Abstract][Full Text] [Related]